Trial Profile
An open-label phase 2 trial of talabostat and gemcitabine [gemzar; Eli Lilly] in patients with stage IV adenocarcinoma of the pancreas
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Jul 2007
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Talabostat (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 07 Jun 2007 Status change from in progress to discontinued.
- 24 Jan 2007 Status change
- 08 Nov 2005 New trial record.